Table 5 The burden of disease in Germany based on prevalence data from the literature
From: Cost of illness and economic burden of chronic lymphocytic leukemia
Sickness fund perspective | Societal perspective | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Year | Study origin | Prevalence | Lower limit (2.5%) | Burden (mean) | Upper limit (97.5%) | Direct costs | Indirect costs | Lower limit (2.5%) | Burden (mean) | Upper limit (97.5%) | |
This study | 2007/2008 | Germany | 4.95 | €187.6 m | €201.1 m | €223.6 m | €189.7 m | €132.0 m | €302.3 m | €321.7 m | €341.3 m |
Orphanet database2 | 2011 | not stated/global | 3.00 | €113.8 m | €122.0 m | €135.6 m | €115.0 m | €80.1 m | €183.4 m | €195.1 m | €207.0 m |
Reis et al.1 | 2000 | Germany | 4.53 | €262.0 m | €52.0 m | €314.0 m | |||||
Reis et al. (adj.)2 | 2007/2008 | Germany | 4.53 | €171.8 m | €184.3 m | €204.9 m | €173.7 m | €121.0 m | €277.0 m | €294.7 m | €312.7 m |
SEER database2 | 2008 | USA | 3.47 | €131.6 m | €141.1 m | €156.9 m | €133.1 m | €92.6 m | €212.1 m | €225.7 m | €239.5 m |